IMMUNOe Research Centers: Clinical Trials

4 trials sponsored by IMMUNOe Research Centers, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 unknown. 2 Phase 4, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 42Completed 1, Unknown 1
Phase 21Completed 1

Follow IMMUNOe Research Centers: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Ruconest - Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder)
Phase 2CompletedIMMUNOe Research Centers402021-01-112025-08-11
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
C1-esterase inhibitor [recombinant] (C1-INH-R) - CVI - Common Variable Immunodeficiency
Phase 4CompletedIMMUNOe Research Centers202018-06-132021-02-15
A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
IVIG - Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Phase 4UnknownIMMUNOe Research Centers212017-11-242019-11-19
The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations
Primary Immunodeficiency
CompletedIMMUNOe Research Centers152015-06-012017-11-13

Conditions studied

Angioedemas, Hereditary (1)  ·  Anxiety Disorders (1)  ·  COVID-19 (1)  ·  Common Variable Immunodeficiency (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Fatigue Syndrome, Chronic (1)  ·  Obsessive-Compulsive Disorder (1)  ·  Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (1)  ·  Pediatric acute-onset neuropsychiatric syndrome (1)  ·  Primary Immunodeficiency Diseases (1)

Interventions

Complement C1 Inhibitor Protein (1)  ·  Immunoglobulins, Intravenous (1)  ·  conestat alfa (1)

Countries

United States (3)

Top investigators

Isaac Melamed, MD (3)

Results publications

PMID 33601937, PMID 33737935, PMID 41281561